中国Patent Term ExtensionUpdates and Changes
2021年5月28日

CNIPA Releases Interim Measures for the Amended Chinese Patent Law Going Into Effect June 1, 2021

Breaking News! We finally have more details about the new Chinese Patent Law which will go into effect on June 1, 2021. The full set of measure can be found at this link. Below are some pertinent points.

No Implementation Rules . . . . Yet

The new Implementation Rules will not be available by June 1, 2021. Accordingly, some submissions to the CNIPA made on or after June 1, 2021 will not be examined until after the Implementation Rules are out.

Patent Term Adjustment for Patent Office Delay

Applicants can request for patent term adjustment for any case granted after June 1, 2021. If applicants have already received a Notice of Allowance, they ensure that the applications will be granted after June 1, 2021 to take advantage of the new law.

Patent Term Extension for Drugs Regulatory Delay

Starting June 1, 2021, Applicants can request for patent term extension for patents covering drugs undergoing regulatory approval, provided that the request is made within 3 months of drug market approval.

Design Patents

A design patent’s application date is crucial for determining whether it falls under the old law or the new law. Most notably, the new law has a 15 year patent term, versus 10 years under the old law. Additionally, applicants can now file for partial designs after June 1, 2021, and claim priority to domestic design application. To take advantage of the longer patent term, applicants should try to ensure their pending design patent applications are filed on or after June 1, 2021.

Open License

The Open License Scheme will be available starting June 1, 2021.

Examination

The grounds for rejecting abnormal applications and methods of nuclear transformation are legally available for all applications regardless of whether they are filed before or after Jun 1, 2021.

In short, none of the above measures are particularly surprising, although it is a bit surprising that the new Implementation Rules are not out yet, and it’s unclear when they will be out. The main message seems to be that, if you are able, delay grant of your pending applications (e.g., by not paying the grant fee until the last minute), in order to take advantage of the multiple advantageous provisions under the new law.

We will keep you updated as soon as any new information is released.

Yolanda Wang is a Principal, Chinese Patent Attorney, and Chinese Patent Litigator at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Sally Yu is a Chinese Patent Attorney at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

First Ever Successful Invalidation Challenge Due to Unauthorized Foreign Filing

2023年3月8日
What does an invention “completed” in China mean? China and the US are similar in that both countries highly value national security, and thus have rules regulating the exportation of technology and information from within their borders. This includes new inventions that arise from within their respective borders. As such, both governments require inventors who […]

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

2024年6月27日
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]

Thin Disclosure but "Bulletproof" Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data

2026年1月8日
In China, innovative drug companies typically rely on their initial composition of matter patents to block out competitors. Other “follow-on” IP, such as those directed towards formulations, polymorphs, and salt forms, are often regarded as less likely to survive invalidation challenges, especially in China where the standard of “person skilled in the art” is so […]

AI is magical but NOT magic! Be specific in your AI patents!

2025年1月9日
What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]

我们的过去活动

Top crossarrow-right